News|Articles|November 18, 2024
Elevating and De-Risking Your Drug Portfolio Strategy With AI
Author(s)Intelligencia AI
Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Eli Lilly Enters $7.8 Billion Agreement to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Treatments
2
Novo Nordisk Launches Multi-Month Subscription Program for Wegovy
3
Merck Enters $838 Million Research & Development Collaboration with Infinimmune
4
How Will MFN’s Effects on Medicare Impact Innovation?
5